Phase 1 trial
Physician and Nurse Beliefs of Phase 1 Trials in Pediatric Oncology
P hase 1 clinical trials in pediatric oncology are the important first step in the evaluation of new treatment regimens for childhood cancer and offer potential treatment for patients for whom all standard therapies have failed. The de-velopment and completion of phase 1 clinical trials are vital to the continued improvement in survival rates for childhood cancers. Although phase 1 trials in pediatric oncology are safe and relatively well tolerated, 1,2 the decision to enroll a child on a phase 1 study can be a complex decision for families. 3 Research indicates that families' decisions to enroll their child on a phase 1 clinical trial are heavily influenced by the opinions of those around them, especially in regard to medical providers. 4, 5 As such, it can be expected that physician and nurse beliefs and expectations concerning phase 1 clinical trials may modify the recommendations made to children and families.
Given these influences on family decision-making processes, it is important to understand the beliefs and expectations that medical providers hold regarding phase 1 clinical trials. To date, little research has been conducted to evaluate provider perceptions, and more specifically, 6Y8 only 1 study has assessed attitudes of both physicians and nurses concurrently. Although results indicate that a majority of physicians and nurses have a positive view of phase 1 trials, a significant subset reports negative perceptions. 8 In addition, no studies have compared specific differences across physician and nurse perceptions, which may be important, given the potential effect these patterns may have on referral recommendations and family decision-making processes.
Whereas pediatric oncologists are responsible for recruiting and enrolling children on phase 1 trials, the role of nurses is also critical. The responsibilities of nurses caring for pediatric oncology patients are diverse, including serving as medical caregiver, advocate, educator, and research assistant. 7 Given the diverse functions of nurses caring for pediatric oncology patients, including the extended periods of intense face-to-face interactions, the impact that nurses have on patient and family decisionmaking processes is important to consider. Although research is limited regarding nurses' role in phase 1 trial enrollment in pediatric oncology, their influence has been documented clinically with adults. In fact, there is growing literature examining their perceptions of clinical trials in regard to adult patient care. In a large study evaluating research nurses' perceptions of phases 1, 2, and 3 clinical trials, most nurses had positive views of phases 2 and 3 trials, although they were less supportive of phase 1 trials. 8 In addition, oncology nurses were more likely to recommend patient participation in phase 3 trials as compared with phases 1 and 2 trials. These findings suggest that nurses are more comfortable with trials where the main goal is to compare the effect of a promising experimental intervention with the current standard of care, as opposed to trials primarily intended to determine the safety and tolerability of a new agent. In addition, the relative lack of exposure to phase 1 trials among many nurses may influence perceptions and elicit biases. Interestingly, this study also analyzed factors associated with perceptions of clinical trials, and compared with physician perceptions, nurse perceptions were more strongly influenced by lack of knowledge and related training and as opposed to occupation. 8 It is possible similar patterns are true in pediatric oncology phase 1 trials, such that experience and training with these protocols are more important than provider occupation.
To better understand medical care providers' perceptions of phase 1 trials in pediatric oncology, the goal of the present study was to evaluate and compare physician and nurse beliefs, expectations, and perceived benefits of pediatric oncology phase 1 clinical trials. n Methods Participants Participants were 94 pediatric oncologists and 122 pediatric nurses practicing at 30 different randomly selected Children's Oncology Group (COG) member institutions in the United States (for list of institutions, e-mail the first author). Inclusion criteria required that participants be practicing within the field of pediatric oncology at a COG member institution.
Survey Procedure
The University of Alabama at Birmingham institutional review board approved the study and waived the requirement for documentation of informed consent. To recruit participants, a random sample of 15 phase 1 consortia institutions and 15 nonYphase 1 consortia institutions was selected from the list of member institutions available on the COG Web site. 
Survey Development
The survey was developed for this study by the investigators (see Document, Supplemental Digital Content 1, for full copy, http://links.lww.com/CN/A1). Survey content was based on previous exploratory work assessing providers' perceptions of phase 1 trials. 6 A draft survey was prepared and subsequently modified after pilot testing with a sample of pediatric oncology physicians and fellows from the investigators' institution as well as experts in the field. The final survey consisted of 21 items. Ten demographic questions assessed participant age, gender, ethnicity, oncology experience, professional responsibilities, and experience with patients referred to or enrolled in phase 1 trials. The remaining 11 questions assessed beliefs about phase 1 trials including treatment decisions, enrollment, potential benefits/risks, and ethical issues. With the exception of the demographic questions, items were either rank ordered or rated on 5-point Likert scales.
Analytic Strategy
Given the lack of data concerning pediatric oncologists and nurse perceptions of phase 1 trials, the primary objectives of the study were to generate descriptive data about medical providers' beliefs concerning phase 1 clinical trials. Comparisons were made between physicians and nurses. For continuous variables, t tests were used to evaluate group differences. For all ranked and rated data, 2 2 tests were used to evaluate differences in the distribution of responses for each group.
n Results
Respondents
Demographic information is presented in Table 1 . Physicians and nurses did not differ on age, ethnicity, years of pediatric oncology experience, or experience with children on phase 1 studies. As expected, physicians were more likely to be male compared with nurses.
Knowledge of Phase 1 Clinical Trials
Responses to questions assessing provider knowledge of phase 1 clinical trials are shown in Table 2 . Physicians were more likely to correctly identify the main goals of phase 1 studies including testing the safety, determining the maximum tolerated dose, and identifying the dose-limiting toxicity of an experimental drug. In addition to being less likely to correctly identify the main goals of phase 1 trials, nurses were more likely to incorrectly endorse goals including determining the efficacy of a drug for a specific disease and extending the life span of a patient. No providers endorsed curing patients as a goal of phase 1 therapy.
Beliefs of Phase 1 Clinical Trials
Provider beliefs about phase 1 clinical trials are presented in Table 3 . The vast majority of physicians and nurses indicated that future children diagnosed with cancer would benefit from phase 1 clinical trials and that trials did not have a negative impact on children's quality of life. Physicians and nurses differed on some aspects of their beliefs, with physicians being less likely to endorse the belief that families understand the goals of and have realistic expectations for phase 1 trials. Consistent with these findings, physicians were more likely to report that consent forms are difficult for families, compared with nurses. Regardless, both groups agreed that children who are old enough to consent for treatment can make treatment decisions. Finally, despite perceptions of difficulty with consent and family understanding, less than half of physicians and nurses believed that phase 1 trials offered false hope for patients and families. 
Enrollment Rationale
Provider questions assessing families' motivations for enrolling on phase 1 clinical trials are shown in Table 4 . The no. 1 reason physicians and nurses believed families enroll on phase 1 clinical trials is to keep hope alive. In line with the belief that families will choose to enroll on phase 1 studies as opposed to stopping treatment, providers also rated that families want more treatment as a top reason for enrolling, although nurses were slightly more likely to endorse this as a reason compared with physicians. Nurses were less likely to believe that families enrolled on phase 1 trials out of guilt compared with physicians; however, this was not a primary reason for enrolling for either group.
Medical Outcomes
Providers' estimates of the potential medical benefits and toxicities experienced by children enrolled on phase 1 clinical trials were variable. Nurses were more likely to estimate that a higher proportion of children would experience medical benefit compared with physicians. In contrast, all physician participants believed that less than 40% would experience medical benefit. In regard to toxicities, the majority of nurses estimated that between 80% and 100% of children would experience significant toxicities or adverse events from phase 1 trials, whereas the majority of physicians believed that less than 40% of children would experience significant toxicities or adverse events (P G .001).
n Discussion
Results of the present study suggest that physicians and nurses differ in their level of understanding of phase 1 clinical trials, with physicians showing a greater level of knowledge regarding the primary goals of these trials. In regard to medical outcomes, nurses were more likely to overestimate the toxicities and underestimate the medical benefits associated with phase 1 clinical trials. Physician responses were more accurate in medical outcome estimations, supported by recent research indicating that phase 1 trials have demonstrated a historical objective response rate of 6.8% for single agent trials and 20.1% for trials of multiple agents. 2 Toxicity has historically been low in phase 1 trials, with only 24% of patients experiencing a dose-limiting toxicity and a drug-related death rate of only 0.5%. 2 Interestingly, despite differences in nurse and physician knowledge of phase 1 goals, perceptions of toxicities, and estimation of benefits, nurses were more likely than physicians to believe that families understand the goals of phase 1 trials and have realistic expectations for outcomes, and they were less likely to endorse that consent forms are difficult to understand for families. More research is needed to evaluate why nurses, despite endorsing more negative perceptions of phase 1 trials compared with physicians, believe that families are knowledgeable and aware of phase 1 trial purposes and outcomes. Despite these differences in knowledge and perception of phase 1 trials, physicians and nurses generally supported the beliefs that future children diagnosed with cancer would benefit from phase 1 clinical trials and that trials did not have a negative impact on children's quality of life. Both groups did acknowledge, however, that families need increased support during this stage of the cancer journey. It is possible that, despite differences in specific understanding of phase 1 trials, physicians and nurses who care for children on phase 1 trials on a regular basis are exposed to both the positive and negative aspects and therefore may have more realistic beliefs regarding the impact of these trials on the lives of children and families outside the medical arena. These findings have important implications in regard to the execution of phase 1 clinical trials and the care of children and families enrolled on these studies. First, as nurses play an everincreasing and integral role in the care of pediatric oncology patients, 9 it is important to recognize the impact they have on children and families' treatment decision making. Increasing efforts to educate nurses regarding the goals and treatmentrelated outcomes (eg, medical benefit, quality of life, toxicity) of children enrolled on phase 1 clinical trials may in turn affect the way nurses interact and influence families considering phase 1 therapy. Currently, no standard educational requirements regarding experimental studies exist for medical providers. Education concerning phase 1 clinical trials therefore likely varies across institutions, occupations, and individual interests and must be taken into consideration when evaluating provider perceptions and knowledge. Institutions participating in these trials or who frequently provide care for children enrolled on these studies may consider in-service workshops or seminars geared toward providers working with these populations.
Taken as a whole, the present study provides insight into the perceptions and beliefs of pediatric oncologists and nurses re-garding phase 1 trials. These findings suggest that continued education of physicians as well as nurses about the goals, execution, and monitoring of phase 1 therapy is important. Methods to improve the consent process may also be necessary to better inform patients and their families.
